我要投票 CONBA康恩贝在中草药行业中的票数:917
· 外 推 电 报 ·
2025-09-21 21:30:29 星期日

【CONBA康恩贝是哪个国家的品牌?】

CONBA康恩贝是什么牌子?「CONBA康恩贝」是 浙江康恩贝制药股份有限公司 旗下著名品牌。该品牌发源于浙江,由创始人胡季强在1993-01-09期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力CONBA康恩贝品牌出海!将品牌入驻外推网,定制CONBA康恩贝品牌推广信息,可以显著提高CONBA康恩贝产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

浙江康恩贝制药股份有限公司是康恩贝集团有限公司的控股子公司,前身为创建于1969年的“兰溪云山制药厂”,经过三十余年发展,现已成长为一家实施全产业链经营,集药材种植、提取、研发、生产、销售于一体的大型医药上市企业。至2015年底,公司有员工近万名,注册资本167,382万元。公司于2004年4月在上海证券交易所上市,股票代码为600572。

公司注册地为浙江省兰溪市,管理总部设在浙江省杭州市,产业布局涵盖浙江的杭州、金华、兰溪,以及江西、云南、内蒙古、四川、贵州、黑龙江等地。公司旗下拥有浙江康恩贝中药有限公司、浙江金华康恩贝生物制药有限公司、云南希陶绿色药业股份有限公司、江西天施康中药股份有限公司、浙江康恩贝医药销售有限公司、杭州康恩贝制药有限公司、上海康恩贝医药有限公司、浙江康恩贝药品研究开发有限公司、内蒙古康恩贝药业有限公司、贵州拜特制药有限公司、浙江珍诚医药在线股份有限公司等多个颇具规模和实力的全资及控股子公司。

公司为国家火炬计划重点高新技术企业、国家创新型企业、国家中药五十强企业、浙江省“五个一批”重点骨干企业、浙江省专利示范企业、国家中药现代化科技产业(浙江)基地示范企业、首批国家知识产权优势企业。经过多年来的技术创新与提升,公司在心脑血管系统用药、泌尿系统用药、抗糖尿病用药、呼吸道系统用药、消化系统用药和抗感染药等药物的研发,以及植物提取分离和结构改造、新型药物释放系统应用等诸多方面积累了诸多的优势。

公司历来十分重视产品品牌和企业品牌的培育和保护,在泌尿系统及心脑血管系统等多个领域建立了消费者熟知与认可的品牌,“康恩贝”、“前列康”、“珍视明”、“天保宁”、“阿乐欣”、“金康”、“金奥康”、“希陶”、“天保康”、“天狮”、“恤彤”等均在各自领域内独放异彩,相比同类竞争产品展现了较为突出的品牌优势,承载着用户的由衷认可。

近年来,公司以“内生增长+投资并购”双轮驱动为发展策略,积极推进内部资源的整合,完善营销网络建设,扎实推进研发、质量体系及企业文化的提升,坚定布局医药电商业务,各项工作取得了良好的进展与成果。

展望未来,公司将继续秉承“为员工幸福尽全心全力为人类健康献至诚至爱”的企业使命,恪守“诚实守信、依法经营、质量第一、用户至上、保障安全、友好环境、幸福员工、奉献社会”八大治企基石,以现代中药和植物药产业为核心,发展化学制药、生物制药业务,同时通过产业互联网+与创新,向药业产业链上游(药材种植加工)和下游(医疗与健康服务)拓展延伸,努力建立基于互联网和全产业链的大健康产业生态!

英文翻译:Zhejiang Kangenbei Pharmaceutical Co., Ltd. is the holding subsidiary of Kangenbei Group Co., Ltd., formerly known as "Lanxi Yunshan pharmaceutical factory" founded in 1969. After more than 30 years of development, it has grown into a large pharmaceutical listed enterprise that implements the whole industrial chain operation and integrates the cultivation, extraction, research and development, production and sales of medicinal materials. By the end of 2015, the company had nearly 10000 employees with a registered capital of 1673.82 million yuan. The company was listed on Shanghai Stock Exchange in April 2004 with stock code of 600572. The company is registered in Lanxi City, Zhejiang Province, with its management headquarters in Hangzhou City, Zhejiang Province. Its industrial layout covers Hangzhou, Jinhua, Lanxi, Jiangxi, Yunnan, Inner Mongolia, Sichuan, Guizhou, Heilongjiang, etc. The company has Zhejiang kangenbe traditional Chinese Medicine Co., Ltd., Zhejiang Jinhua kangenbe Biological Pharmaceutical Co., Ltd., Yunnan Xitao green Pharmaceutical Co., Ltd., Jiangxi tianshikang traditional Chinese Medicine Co., Ltd., Zhejiang kangenbe Pharmaceutical Sales Co., Ltd., Hangzhou kangenbe Pharmaceutical Co., Ltd., Shanghai kangenbe Pharmaceutical Co., Ltd., Zhejiang kangenbe pharmaceutical research and Development Co., Ltd , Inner Mongolia Kangenbei Pharmaceutical Co., Ltd., Guizhou Beite Pharmaceutical Co., Ltd., Zhejiang Zhencheng pharmaceutical online Co., Ltd. and other large-scale and powerful wholly-owned and holding subsidiaries. The company is a key high-tech enterprise of national torch plan, a national innovative enterprise, a top 50 enterprise of national traditional Chinese medicine, a key backbone enterprise of "five in one batch" in Zhejiang Province, a patent demonstration enterprise in Zhejiang Province, a demonstration enterprise of national modern science and technology industry (Zhejiang) base of traditional Chinese medicine, and the first batch of national intellectual property advantage enterprises. After years of technological innovation and upgrading, the company has accumulated many advantages in the research and development of cardiovascular and cerebrovascular system drugs, urinary system drugs, anti diabetes drugs, respiratory system drugs, digestive system drugs and anti infective drugs, as well as plant extraction and separation and structural transformation, new drug release system applications and many other aspects. The company has always attached great importance to the cultivation and protection of product brands and enterprise brands. It has established brands well known and recognized by consumers in various fields such as urinary system, cardio cerebrovascular system, etc., "Kangenbei", "QianLieKang", "Zhenshiming", "Tianbaoning", "alexin", "Jinkang", "jinaokang", "Xitao", "Tianbaokang", "Tianshi", "Xiangtong" ”All of them are unique in their respective fields. Compared with similar competitive products, they show more prominent brand advantages and bear the sincere recognition of users. In recent years, the company has taken "endogenous growth + investment merger and acquisition" as its development strategy, actively promoted the integration of internal resources, improved the construction of marketing network, solidly promoted the improvement of R & D, quality system and corporate culture, firmly arranged the pharmaceutical e-commerce business, and made good progress and achievements in various works. Looking forward to the future, the company will continue to uphold the corporate mission of "do our best for the well-being of our employees and the best for human health", adhere to the eight corporate cornerstones of "honesty and trustworthiness, operation according to law, quality first, user first, security, environment-friendly, happy employees, and dedication to the society", and develop chemical pharmacy and biopharmaceutical industry with modern Chinese medicine and plant medicine industry as the core Meanwhile, the industry will expand to the upstream of the pharmaceutical industry chain (medicinal plant processing) and downstream (medical and health services) through the Internet plus and innovation, and strive to build a healthy industrial ecosystem based on the Internet and the whole industry chain.

本文链接: https://www.waitui.com/brand/ac7af194f.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

山西汾酒:股东华创鑫睿计划减持不超1.33%公司股份

36氪获悉,山西汾酒发布公告,根据联和基金相关合作协议,其面临基金到期退出安排,需要减持其间接持有的全部公司股份,因此持股5%以上股东华创鑫睿本次拟通过大宗交易方式减持不超过1620.06万股(含本数),计划减持比例不超过1.33%;自本次减持计划公开披露之日起15个交易日后的3个月内(含3个月期满当日)实施。

2小时前

中信证券:三方面的技术趋势将推动刻蚀设备的用量和重要性提升

36氪获悉,中信证券预计,至少以下三方面的技术趋势将推动刻蚀设备的用量和重要性提升:1.光刻多重图案化路线的采用;2.三维堆叠存储和近存计算需求;3.底层晶体管结构升级。长期看,半导体设备国产化方向明确,短期来看,下游扩产有望驱动行业进入新一轮增长期。建议关注国内刻蚀设备厂商以及相关配套设备、零部件企业机会。

2小时前

中信证券:右侧趋势品种继续聚焦资源、消费电子、创新药和游戏

36氪获悉,中信证券研报表示,目前整体的行业选择框架依然是围绕资源+新质生产力+出海。资源股在供给受限以及全球地缘动荡的预期推动下,从周期属性转向偏红利属性会带来估值体系重构,博弈美联储降息的资金退潮带来的波动可以忽略。更大的中期线索还是中国制造业龙头的全球化,将份额优势转化为定价权和利润率提升,带来超越本国经济基本面的市值增长,从而逐步打破行情与基本面背离且全靠流动性驱动的错误认知。配置结构上,保持定力,右侧趋势品种继续聚焦资源、消费电子、创新药和游戏;左侧配置关注化工和军工;产业趋势层面,近期重点关注AI从云侧逻辑开始向端侧逻辑扩散。

2小时前

环球印务:股东香港原石拟减持不超1%公司股份

36氪获悉,环球印务发布公告,持股10.98%的股份的股东香港原石国际有限公司(简称“香港原石”)计划以集中竞价交易合计减持不超过320.04万股公司股份,占公司总股本比例的1%。

2小时前

冠中生态:筹划控制权变更事项,股票停牌

36氪获悉,冠中生态发布公告,公司控股股东青岛冠中投资集团有限公司及实际控制人李春林和许剑平正在筹划公司控制权变更相关事宜,可能导致公司控股股东及实际控制人发生变更。经申请,公司股票及可转换公司债券自2025年9月22日起停牌,预计停牌时间不超过2个交易日。停牌期间,公司可转换公司债券“冠中转债”将暂停转股。

2小时前

本页详细列出关于CONBA康恩贝的品牌信息,含品牌所属公司介绍,CONBA康恩贝所处行业的品牌地位及优势。
咨询